Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cappellini

Showing results (701-710 of 863) with videos related to

Pageof 87
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|August 14, 2024
Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapyLauretta Levati, Claudio Tabolacci, Antonio Facchiano, et al.
Haematologica|October 13, 2004
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamineCaterina Borgna-Pignatti, Simone Rugolotto, Piero De Stefano, et al.
British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.
Annals of the New York Academy of Sciences|December 13, 2005
Survival and complications in thalassemiaC Borgna-Pignatti, M D Cappellini, P De Stefano, et al.
American Journal of Hematology|November 6, 2018
Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO<sup>©</sup> )Ali Taher, Maria Domenica Cappellini, Vip Viprakasit, et al.
Oncotarget|November 24, 2015
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κBFrancesca Buontempo, Ester Orsini, Annalisa Lonetti, et al.
Recenti Progressi in Medicina|October 2, 2025
Towards learning healthcare systems in Italy: opportunities and challenges of AI at point-of-careLuigi De Angelis, Alessio Pivetta, Francesco Baglivo, et al.
Haematologica|July 5, 2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga, Renzo Galanello, Gian Luca Forni, et al.
Scientific Reports|February 23, 2012
Application and comparison of large-scale solution-based DNA capture-enrichment methods on ancient DNAMaría C Avila-Arcos, Enrico Cappellini, J Alberto Romero-Navarro, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
Pageof 87

Showing results (701-710 of 863) with videos related to

Sort By:
Pageof 87
Journal of Experimental & Clinical Cancer Research : CR|August 14, 2024
Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapyLauretta Levati, Claudio Tabolacci, Antonio Facchiano, et al.
Haematologica|October 13, 2004
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamineCaterina Borgna-Pignatti, Simone Rugolotto, Piero De Stefano, et al.
British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.
Annals of the New York Academy of Sciences|December 13, 2005
Survival and complications in thalassemiaC Borgna-Pignatti, M D Cappellini, P De Stefano, et al.
American Journal of Hematology|November 6, 2018
Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO<sup>©</sup> )Ali Taher, Maria Domenica Cappellini, Vip Viprakasit, et al.
Oncotarget|November 24, 2015
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κBFrancesca Buontempo, Ester Orsini, Annalisa Lonetti, et al.
Recenti Progressi in Medicina|October 2, 2025
Towards learning healthcare systems in Italy: opportunities and challenges of AI at point-of-careLuigi De Angelis, Alessio Pivetta, Francesco Baglivo, et al.
Haematologica|July 5, 2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga, Renzo Galanello, Gian Luca Forni, et al.
Scientific Reports|February 23, 2012
Application and comparison of large-scale solution-based DNA capture-enrichment methods on ancient DNAMaría C Avila-Arcos, Enrico Cappellini, J Alberto Romero-Navarro, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
Pageof 87